|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1998-2-6
|
|
pubmed:abstractText |
Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0003-9942
|
|
pubmed:author |
pubmed-author:AtkinsonJ HJH,
pubmed-author:BrownS JSJ,
pubmed-author:EatonE MEM,
pubmed-author:FeasterDD,
pubmed-author:GoldschmidtsW LWL,
pubmed-author:GoodkinKK,
pubmed-author:HeatonR KRK,
pubmed-author:HeseltineP NPN,
pubmed-author:RochonJJ,
pubmed-author:SchneiderLL,
pubmed-author:SobelEE,
pubmed-author:StoverE SES,
pubmed-author:VitielloBB,
pubmed-author:WilkieF LFL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
41-51
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9443710-AIDS Dementia Complex,
pubmed-meshheading:9443710-Administration, Intranasal,
pubmed-meshheading:9443710-Adolescent,
pubmed-meshheading:9443710-Adult,
pubmed-meshheading:9443710-CD4 Lymphocyte Count,
pubmed-meshheading:9443710-Double-Blind Method,
pubmed-meshheading:9443710-Female,
pubmed-meshheading:9443710-Humans,
pubmed-meshheading:9443710-Male,
pubmed-meshheading:9443710-Middle Aged,
pubmed-meshheading:9443710-Neuropsychological Tests,
pubmed-meshheading:9443710-Peptide T,
pubmed-meshheading:9443710-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
|
|
pubmed:affiliation |
Department of Medicine, University of Southern California, Los Angeles 90033, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
